BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28272408)

  • 21. Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk.
    Liu J; Prager-van der Smissen WJ; Schmidt MK; Collée JM; Cornelissen S; Lamping R; Nieuwlaat A; Foekens JA; Hooning MJ; Verhoef S; van den Ouweland AM; Hogervorst FB; Martens JW; Hollestelle A
    Sci Rep; 2016 Jul; 6():30026. PubMed ID: 27424772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease.
    Witte JS; Mefford J; Plummer SJ; Liu J; Cheng I; Klein EA; Rybicki BA; Casey G
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):675-80. PubMed ID: 23396964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HOXB13 mutations in a population-based, case-control study of prostate cancer.
    Stott-Miller M; Karyadi DM; Smith T; Kwon EM; Kolb S; Stanford JL; Ostrander EA
    Prostate; 2013 May; 73(6):634-41. PubMed ID: 23129385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Study of Human FBXW7 Deleterious nsSNP's Functional Inference and Susceptibility to Gynaecological Cancer.
    Vasuki KA; Christy HJ
    Appl Biochem Biotechnol; 2022 Jan; 194(1):407-433. PubMed ID: 34817806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.
    Storebjerg TM; Høyer S; Kirkegaard P; Bro F; ; Ørntoft TF; Borre M; Sørensen KD
    BJU Int; 2016 Oct; 118(4):646-53. PubMed ID: 26779768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for familial and hereditary prostate cancer.
    Lynch HT; Kosoko-Lasaki O; Leslie SW; Rendell M; Shaw T; Snyder C; D'Amico AV; Buxbaum S; Isaacs WB; Loeb S; Moul JW; Powell I
    Int J Cancer; 2016 Jun; 138(11):2579-91. PubMed ID: 26638190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic factors influencing prostate cancer risk in Norwegian men.
    Chen H; Ewing CM; Zheng S; Grindedaal EM; Cooney KA; Wiley K; Djurovic S; Andreassen OA; Axcrona K; Mills IG; Xu J; Maehle L; Fosså SD; Isaacs WB
    Prostate; 2018 Feb; 78(3):186-192. PubMed ID: 29181843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy.
    Schroeck FR; Zuhlke KA; Siddiqui J; Siddiqui R; Cooney KA; Wei JT
    J Urol; 2013 Mar; 189(3):849-53. PubMed ID: 23036981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial.
    Chen Z; Greenwood C; Isaacs WB; Foulkes WD; Sun J; Zheng SL; Condreay LD; Xu J
    Carcinogenesis; 2013 Jun; 34(6):1260-4. PubMed ID: 23393222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer.
    Saunders EJ; Dadaev T; Leongamornlert DA; Jugurnauth-Little S; Tymrakiewicz M; Wiklund F; Al Olama AA; Benlloch S; Neal DE; Hamdy FC; Donovan JL; Giles GG; Severi G; Gronberg H; Aly M; Haiman CA; Schumacher F; Henderson BE; Lindstrom S; Kraft P; Hunter DJ; Gapstur S; Chanock S; Berndt SI; Albanes D; Andriole G; Schleutker J; Weischer M; Nordestgaard BG; Canzian F; Campa D; Riboli E; Key TJ; Travis RC; Ingles SA; John EM; Hayes RB; Pharoah P; Khaw KT; Stanford JL; Ostrander EA; Signorello LB; Thibodeau SN; Schaid D; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park JY; Kaneva R; Batra J; Clements JA; Teixeira MR; Xu J; Mikropoulos C; Goh C; Govindasami K; Guy M; Wilkinson RA; Sawyer EJ; Morgan A; ; ; ; ; Easton DF; Muir K; Eeles RA; Kote-Jarai Z
    PLoS Genet; 2014 Feb; 10(2):e1004129. PubMed ID: 24550738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.
    Beebe-Dimmer JL; Hathcock M; Yee C; Okoth LA; Ewing CM; Isaacs WB; Cooney KA; Thibodeau SN
    Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1366-72. PubMed ID: 26108461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in European descendants: a meta-analysis of 24,213 cases and 73, 631 controls.
    Shang Z; Zhu S; Zhang H; Li L; Niu Y
    Eur Urol; 2013 Jul; 64(1):173-6. PubMed ID: 23518396
    [No Abstract]   [Full Text] [Related]  

  • 33. Germline mutations in HOXB13 and prostate-cancer risk.
    Ewing CM; Ray AM; Lange EM; Zuhlke KA; Robbins CM; Tembe WD; Wiley KE; Isaacs SD; Johng D; Wang Y; Bizon C; Yan G; Gielzak M; Partin AW; Shanmugam V; Izatt T; Sinari S; Craig DW; Zheng SL; Walsh PC; Montie JE; Xu J; Carpten JD; Isaacs WB; Cooney KA
    N Engl J Med; 2012 Jan; 366(2):141-9. PubMed ID: 22236224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland.
    Kluźniak W; Wokołorczyk D; Kashyap A; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Gołąb A; Gliniewicz B; Sikorski A; Switała J; Borkowski T; Borkowski A; Antczak A; Wojnar L; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Akbari MR; Lubiński J; Narod SA; Cybulski C;
    Prostate; 2013 Apr; 73(5):542-8. PubMed ID: 23334858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer.
    Handorf E; Crumpler N; Gross L; Giri VN
    J Genet Couns; 2014 Jun; 23(3):371-6. PubMed ID: 24310616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synonymous Polymorphisms in HOXB13 as a Protective Factor for Prostate Cancer.
    Albitar F; Diep K; Ma W; Albitar M
    J Cancer; 2015; 6(5):409-11. PubMed ID: 25874003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.
    Laitinen VH; Wahlfors T; Saaristo L; Rantapero T; Pelttari LM; Kilpivaara O; Laasanen SL; Kallioniemi A; Nevanlinna H; Aaltonen L; Vessella RL; Auvinen A; Visakorpi T; Tammela TL; Schleutker J
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):452-60. PubMed ID: 23292082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.
    Liu J; Prager-van der Smissen WJC; Collée JM; Bolla MK; Wang Q; Michailidou K; Dennis J; Ahearn TU; Aittomäki K; Ambrosone CB; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Augustinsson A; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Bernstein L; Bogdanova NV; Bogdanova-Markov N; Bojesen SE; Brauch H; Brenner H; Briceno I; Brucker SY; Brüning T; Burwinkel B; Cai Q; Cai H; Campa D; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Choi JY; Christiaens M; Clarke CL; ; Couch FJ; Czene K; Daly MB; Devilee P; Dos-Santos-Silva I; Dwek M; Eccles DM; Eliassen AH; Fasching PA; Figueroa J; Flyger H; Fritschi L; Gago-Dominguez M; Gapstur SM; García-Closas M; García-Sáenz JA; Gaudet MM; Giles GG; Goldberg MS; Goldgar DE; Guénel P; Haiman CA; Håkansson N; Hall P; Harrington PA; Hart SN; Hartman M; Hillemanns P; Hopper JL; Hou MF; Hunter DJ; Huo D; ; Ito H; Iwasaki M; Jakimovska M; Jakubowska A; John EM; Kaaks R; Kang D; Keeman R; Khusnutdinova E; Kim SW; Kraft P; Kristensen VN; Kurian AW; Le Marchand L; Li J; Lindblom A; Lophatananon A; Luben RN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mariapun S; Matsuo K; Maurer T; Mavroudis D; Meindl A; Menon U; Milne RL; Muir K; Mulligan AM; Neuhausen SL; Nevanlinna H; Offit K; Olopade OI; Olson JE; Olsson H; Orr N; Park SK; Peterlongo P; Peto J; Plaseska-Karanfilska D; Presneau N; Rack B; Rau-Murthy R; Rennert G; Rennert HS; Rhenius V; Romero A; Ruebner M; Saloustros E; Schmutzler RK; Schneeweiss A; Scott C; Shah M; Shen CY; Shu XO; Simard J; Sohn C; Southey MC; Spinelli JJ; Tamimi RM; Tapper WJ; Teo SH; Terry MB; Torres D; Truong T; Untch M; Vachon CM; van Asperen CJ; Wolk A; Yamaji T; Zheng W; Ziogas A; Ziv E; Torres-Mejía G; Dörk T; Swerdlow AJ; Hamann U; Schmidt MK; Dunning AM; Pharoah PDP; Easton DF; Hooning MJ; Martens JWM; Hollestelle A
    Sci Rep; 2020 Jun; 10(1):9688. PubMed ID: 32546843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HOXB13 contributes to G1/S and G2/M checkpoint controls in prostate.
    Hamid SM; Cicek S; Karamil S; Ozturk MB; Debelec-Butuner B; Erbaykent-Tepedelen B; Varisli L; Gonen-Korkmaz C; Yorukoglu K; Korkmaz KS
    Mol Cell Endocrinol; 2014 Mar; 383(1-2):38-47. PubMed ID: 24325868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
    Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.